Successful Control of Acute Myelofibrosis with Lenalidomide
Author Information
Author(s): G. Vassilopoulos, M. Palassopoulou, K. Zisaki, M. Befani, E. Bouronikou, N. Giannakoulas, E. Stathopoulou, P. Matsouka
Primary Institution: University Hospital of Larisa
Hypothesis
Can lenalidomide effectively treat acute myelofibrosis?
Conclusion
Lenalidomide treatment led to normalization of blood counts and reduced the need for growth factor support in a patient with acute myelofibrosis.
Supporting Evidence
- The patient was transfusion-independent after 6 months of lenalidomide treatment.
- Bone marrow biopsies showed improvement in fibrosis and cellularity after treatment.
- Lenalidomide is known for its immunomodulatory effects, which may have contributed to the patient's recovery.
Takeaway
A woman with a rare blood disease got better after taking a medicine called lenalidomide, which helped her blood counts return to normal.
Methodology
The patient was treated with lenalidomide for 21 days along with growth factor support after failing other treatments.
Limitations
The study is based on a single case report, limiting generalizability.
Participant Demographics
59-year-old female patient.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website